Actual condition survey and examination of predictive factor for nonalcoholic fatty liver disease among the patients with metabolic diseases

Actual condition survey and examination of predictive factor for nonalcoholic fatty liver disease among the patients with metabolic diseases - Examination of actual condition and predictive factor for NAFLD

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000016379

Enrollment

5000

Registered

2015-01-29

Start date

2013-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nonalcoholic fatty liver disease (NAFLD) Nonalcoholic steatohepatitis (NASH) Metabolic disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Male and female over twenty years of age 2. Patients agree with participation

Exclusion criteria

Exclusion criteria: 1. Patients with pregnancy and lactation 2. Patients with poor condition 3. Persons judged inappropriate for this study

Design outcomes

Primary

Measure	Time frame
1.Identify prevalence of NAFLD among the patients with metabolic disease. 2.Explore the associated factor between pathophysiology of NAFLD, and lifestyle and biochemical test and physical examination. 3.Investigate the predictive factor for onset and exacerbating factor of NAFLD among the patients with metabolic disease. 4.Investigate the predictive factor for onset and exacerbating factor of metabolic diseases among the patients with metabolic disease among the patients with metabolic disease. 5.Investigate prevalence and associated factor of cancer onset among the patients with metabolic disease. 6.Investigate prevalence and associated factor of arteriosclerotic disease among the patients with metabolic disease.	—

Measure

Time frame

1.Identify prevalence of NAFLD among the patients with metabolic disease. 2.Explore the associated factor between pathophysiology of NAFLD, and lifestyle and biochemical test and physical examination. 3.Investigate the predictive factor for onset and exacerbating factor of NAFLD among the patients with metabolic disease. 4.Investigate the predictive factor for onset and exacerbating factor of metabolic diseases among the patients with metabolic disease among the patients with metabolic disease. 5.Investigate prevalence and associated factor of cancer onset among the patients with metabolic disease. 6.Investigate prevalence and associated factor of arteriosclerotic disease among the patients with metabolic disease.

—

Secondary

Measure	Time frame
1.Compare the diagnosability of NAFLD/NASH between associated factor of NAFLD in this study and score system of NAFLD/NASH 2.Evaluate the correlation between associated factor of NAFLD in this study and serum marker of NAFLD/NASH	—

Countries

Japan

Contacts

Public ContactTeruki Miyake

Ehime University Graduate School of Medicine Department of Gastroenterology and Metabology

teruki-ygc@umin.ac.jp+81899605308

Outcome results